rethinkPeptides Search
Menu
Home / Research library
Study breakdown

SGLT2 + GLP-1 combination provides synergistic cardiometabolic protection without new safety signals in systematic review

RPEP-137712025Tantawy, Dalia; Musa Rabih, Maram Rabih; Ibrahim Mohamed, Razan Seifeldin; Abdelrahman Ali, Malaz Omer; Mohammed Saad Aldeen, Rayan Saad Aldeen; Ahmed Abdelkarim, Ali Omer; Awadalkreem Mohamedzain, Tawasul Greeballah
evidence
The takeaway

Systematic review of 9 RCTs confirms SGLT2i + GLP-1RA combination provides additive MACE reduction, superior glycemic control, greater weight loss, and BP reduction versus monotherapy, without new or unexpected safety signals.

Additive benefits, no new risks

SGLT2i + GLP-1RA combination provides synergistic cardiometabolic protection with no unexpected safety signals across 9 randomized trials

What the researchers found

GLP-1RA reduced MACE/HFH regardless of SGLT2i background. SGLT2i benefits maintained with GLP-1RA. Combination: superior HbA1c, weight, SBP reduction. No new safety signals. Manageable GI and genital infection risks. 9 RCTs (2020-2025).

Why it matters

Guidelines now recommend both drug classes for high-risk T2DM. This review confirms the combination is synergistic and safe, supporting dual therapy over sequential monotherapy.

How the study worked

PRISMA systematic review. PubMed, Scopus, Embase, Web of Science (2020-2025). 9 RCTs including CVOTs and mechanistic studies. Cochrane RoB 2.

What this study cannot tell us

Post-hoc analyses from trials not designed for combination. Dedicated prospective combination trials still needed. Cost/access barriers to dual therapy.

How to read the evidence

Systematic review of 9 RCTs with Cochrane quality assessment. Post-hoc evidence; dedicated combination trials needed.

When this study was published

Published in 2025; literature 2020-2025.

The bigger picture

Combination SGLT2i + GLP-1RA may become the standard of care for high-risk T2DM, addressing cardiac, renal, metabolic, and weight outcomes simultaneously.

Questions still open

  • Should all high-risk T2DM patients start both drugs simultaneously?
  • Will a dedicated combination RCT provide stronger evidence?
  • How do triple combinations (SGLT2i + GLP-1RA + finerenone) perform?

Common questions

Is it safe to take both an SGLT2 inhibitor and a GLP-1 drug?
Yes. This review of 9 clinical trials found the combination provides additive heart and kidney protection without any new or unexpected safety issues. The only side effects are the ones already known for each drug individually.
Why take two diabetes drugs at once?
SGLT2 inhibitors and GLP-1 drugs protect different organ systems through different mechanisms. Together they provide better blood sugar control, more weight loss, lower blood pressure, AND greater cardiovascular and kidney protection than either alone.

Read the original research

Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review.

Cureus, 17(11), e96218

View on PubMed ↗Publisher’s paper ↗

Citation

Tantawy, Dalia; Musa Rabih, Maram Rabih; Ibrahim Mohamed, Razan Seifeldin; Abdelrahman Ali, Malaz Omer; Mohammed Saad Aldeen, Rayan Saad Aldeen; Ahmed Abdelkarim, Ali Omer; Awadalkreem Mohamedzain, Tawasul Greeballah. (2025). Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review.. Cureus, 17(11), e96218. https://doi.org/10.7759/cureus.96218